BERKELEY, Calif., July 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its second quarter 2006 financial results on Thursday, July 27, 2006.
The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of second quarter 2006 financial results.
The webcast can be accessed on Dynavax Technologies' website at http://www.dynavax.com . The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
An audio replay of the webcast will be available until August 3, 2006 by dialing 888-286-8010; conference identification number 67521357. International callers can dial 617-801-6888; conference identification number 67521357.
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR-9 agonist-based products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine that is currently in a Phase 3 clinical trial; SUPERVAX, a hepatitis B vaccine; a cancer therapy currently in a Phase 2 clinical trial in non-Hodgkins lymphoma; an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial; and preclinical programs in hepatitis B and hepatitis C therapy.
SOURCE Dynavax Technologies Corporation
Jane M. Green, PhD, of Dynavax Technologies Corporation, Corporate Communications, +1-510-665-4630, or firstname.lastname@example.org